这两天Seedance 2.0横空出世，让"人人可做AI导演"照进现实，再次掀起AI（人工智能）热潮。AI卷得火热，机器人"新贵"也不甘落后，直接把战场拉到 了"晚会赛道"。 一边是宇树科技、魔法原子等砸下真金白银，把自家机器人送上总台春晚大舞台；另一边，有玩家另辟蹊径，让200多台机器人集体"打工"，办了一台专属 于机器人的"晚会"。 耍醉拳、舞火棍、演小品、变魔术、跳华尔兹2月8日，由智元AGIBOT主办、机器人"主演"的机器人晚会《机器人奇妙夜》（AGIBOT NIGHT 2026）上 线，并在智元AGIBOT及"稚晖君"全网账号、芒果TV、哔哩哔哩、抖音、新华社等平台全球直播。社交平台上，网友们议论纷纷："机器人跳华尔兹，比人 还曼妙！" 《算法华尔兹》 图片来源：企业供图 作为全球首个大型机器人晚会的负责人，邱恒接受了《每日经济新闻》记者的采访，他分享了这台"机器人晚会"背后的更多细节：250多台机器人，参与的 工程师数量不到机器人数量的十分之一，活动几乎零成本。 对于备受关注的"上春晚"，智元公司方面向《每日经济新闻》记者回应："我们非常希望能登上总台春晚，但公司整体预算有限，优先保障研发费用。" ...

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The approval of the fourth indication for the subsidiary's core asset SKB264 in China is a positive development, indicating that the sales of innovative drugs are gradually materializing, and there is an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights that Kelun Pharmaceutical, as a leading company in the industry, has stable business development, and the first product from Kelun Botai is about to be launched overseas, which supports the outlook for the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year increase of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report provides a detailed financial forecast, including revenue and net profit projections for the next five years, indicating fluctuations in growth rates [5][16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report notes that the company has a total equity of 23,708 million yuan and a net asset per share of 14.84 yuan [9] Clinical Development - Kelun Botai has initiated nine registration clinical studies for SKB264 in China, with significant clinical trial results indicating improved progression-free survival (PFS) and overall survival (OS) rates compared to chemotherapy [13]

证券日报网讯 2月11日，复星医药在互动平台回答投资者提问时表示，复宏汉霖是公司的控股子公司， 其收入全额纳入公司合并报表范围。创新药品收入方面，2025年公司前三季度创新药品收入超人民币67 亿元，较上年同期增长18.09%，并呈现稳健增长态势。随着2025年复迈宁、复妥宁、万缇乐、普瑞尼 等产品新获纳入国家医保目录以及奕凯达新获纳入商保创新药品目录，公司创新药品有望进一步扩大市 场覆盖、为收入提供增量。此外，公司创新管线临床开发的持续推进，也有望为后续年度公司创新药品 收入的增长提供新的动力。 （文章来源：证券日报） ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Roche's Fenebrutinib has successfully completed its Phase III clinical trial, demonstrating non-inferiority in reducing disability progression in primary progressive multiple sclerosis (PPMS) patients compared to the approved therapy Ocrevus, with a 12% reduction in risk [5]. - The pharmaceutical sector showed a slight increase of 0.60% on February 9, 2025, outperforming the CSI 300 index by 0.49 percentage points, ranking 7th among 31 sub-industries [4]. - Among sub-industries, medical research outsourcing (+1.94%), other biological products (+0.69%), and medical consumables (+0.59%) performed well, while vaccines (-0.70%), offline pharmacies (-0.49%), and pharmaceutical distribution (-0.41%) lagged [4]. Sub-industry Summary - Chemical pharmaceuticals: No rating [3] - Traditional Chinese medicine production: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other pharmaceutical sectors: Neutral [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 為控股子公司提供擔保的進展公告》，僅供參閱。 承董事會命 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年2 月1 1 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅 ...

证券代码：600196 证券简称：复星医药 公告编号：临 2026-021 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 名称 | 复星健康 | | --- | --- | --- | | | 本次担保金额 | 人民币 2,000 万元 | | 被担保方 1 | 截至 2026 年 2 月 11 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 折合人民币约 215,268 万元 | | | 是否在前期预计额度内 | 是 □否 □不适用：________ | | | 本次担保是否有反担保 | □否 □不适用：________ 是 | | | 名称 本次担保金额 | 复星诊断长沙 人民币 2,500 万元 | | 被担保方 2 | 截至 2026 年 2 月 11 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 人民币 14,918 万元 | | | 是否在前期预计额度内 | 是 □ ...

21世纪经济报道记者唐唯珂 入境医疗火了起来，全球范围来看跨境医疗并非新鲜事。 目前，全球患者的跨境流动大致呈现两种路径：一类是"向更高水平集中"，另一类则是"向更高性价比 转移"。 发展中国家的高净值人群，是"向上走"的主力。东南亚、中亚等地区的富裕阶层，由于本国高端医疗供 给有限，往往选择赴美、日、英等医疗高地，寻求更先进的技术与更成熟的治疗方案。 另一边，是发达国家中低收入群体的"向下走"。在英国、加拿大等高福利国家，为了规避动辄半年的手 术排队或昂贵的自费项目，患者则在全球寻找更具性价比、效率更高的医疗服务。 随着免签红利释放，"来华就医"热度攀升。在TikTok与小红书上，海外博主纷纷晒出就诊账单，来华看 病似乎成为新风向。 "在庞大的跨境市场之中，各国提供了一些借鉴经营，结合自己的优势和现实医疗基础有序发展产业， 才能规避可能出现的潜在问题。"华南某医疗机构从业人士向21世纪经济报道记者表示。 流动的市场：他山之石 医疗资源的差异,决定了跨境医疗这个流动的全球市场。 行研机构Wise Guy Reports预计，全球跨境医疗旅游市场将从2024年的1142亿美元增长到2032年的2500 亿美元， ...

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the performance of the Hong Kong stock market, particularly focusing on the Hang Seng Index and sector performances, including healthcare, consumer goods, and real estate [1][2]. Core Insights and Arguments - The Hang Seng Index increased by 0.5%, with the National Enterprises Index and Technology Index both rising by 0.8% [1] - The healthcare sector led the market with a gain of 3.0%, while consumer staples and real estate sectors lagged, declining by 0.5% and 0.6% respectively [1] - Total trading volume reached HKD 13.4 billion, with a net inflow of USD 147 million from southbound trading [1] - Despite a lack of strong catalysts, market momentum and liquidity remained positive, with investors cautious ahead of the upcoming long holiday [1] Sector-Specific Performance - The biotechnology and artificial intelligence sectors outperformed the market, while the tourism sector underperformed despite seasonal catalysts related to the Spring Festival [2] - Notable stock movements included: - CSPC Pharmaceutical Group up by 6.3% - Fosun Pharma up by 5.6% - Innovent Biologics up by 5.3%, driven by collaboration news with Eli Lilly [2] - Innoscience, a semiconductor company, saw a 7.5% increase, supported by 15% of its trading volume coming from southbound investors [3] - Kuaishou rose by 1.6% after a previous decline, indicating technical support [3] Additional Important Insights - The trading desk showed a preference for buying defensive stocks such as insurance and logistics while selling off positions in cement and e-commerce sectors [2] - The interest in the "Monster" IP (Labubu) from Pop Mart saw a delivery volume exceeding 100 million pieces, although southbound investors were selling the stock [3] - The short interest in Pop Mart decreased to 8.1 times DTC, representing 18% of its free float [3]

Policy Developments - The National Health Commission of China has prohibited beauty institutions, hair salons, and nail salons from conducting "light medical beauty" projects due to rising concerns over safety and qualifications in the medical beauty industry [2] Industry Developments - A new international trading platform for medical devices and instruments has been launched in Tianjin, aimed at facilitating "global buying and selling" of medical equipment, enhancing cross-border cooperation, and reducing international trade costs [3] - The Chinese Center for Disease Control and Prevention reported a general decline in acute respiratory infectious disease epidemics, with flu levels remaining low across the country [14] Drug and Device Approvals - Fosun Pharma announced that its subsidiary Shanghai Chaohui Pharmaceutical's application for the registration of Bupivacaine Hydrochloride Gel has been accepted by the National Medical Products Administration [5] - GlaxoSmithKline's RSV vaccine Arexvy has had its registration application accepted in China, with expectations for approval by 2027 [6] Financial Reports - AstraZeneca reported a total global revenue of $58.739 billion for 2025, marking an 8% year-on-year increase, with revenue from China reaching $6.654 billion, a 4% increase [8] Capital Market Activities - Beijing Supervision Biotechnology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with investments from multiple funds aimed at advancing its technology in clinical and brain disease intervention [10] - Hangzhou Tangji Medical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange [11] Industry Events - The first round of national centralized procurement for 316 commonly used drugs has been conducted, involving over 5,100 medical institutions and 1,091 domestic and foreign companies, with results expected to be implemented by March 2026 [13] - Samsung Medical's subsidiary has been recommended as a candidate for a project worth approximately 321 million yuan with Southern Power Grid [15]

Key Points - Infineon expects the gallium nitride market to achieve a compound annual growth rate of 44% from 2025 to 2030 [1] - Huahong Semiconductor has received approval from the Shanghai State-owned Assets Supervision and Administration Commission for its asset purchase and fundraising plan [1] - Yunnan Energy Holdings is planning to acquire a stake in Xiantian Computing Technology Co., Ltd. and is in the process of acquiring controlling interest in Zhengzhou Heying Data Co., Ltd. [1] - Heng Rui Medicine's subsidiary has had a new indication for its injectable drug accepted by the National Medical Products Administration [1] - Fosun Pharma's subsidiary has had its drug registration application accepted by the National Medical Products Administration [1] Investment, Contracts, and Bids - Zhongtung High-tech plans to invest 145 million yuan in a new project to produce 30 million PCB drill needles annually [1] - China Railway Construction recently won major contracts totaling 45.142 billion yuan [1] - Tianneng Wind Power has signed new offshore engineering contracts worth 870 million yuan [1] - Yunjigroup's wholly-owned subsidiary has signed an EPC general contracting agreement worth 1.331 billion yuan, accounting for 86.66% of the company's audited revenue for 2024 [1] Performance - SMIC reported a net profit of 1.223 billion yuan for Q4 2025, representing a year-on-year increase of 23.2% [1] - Huichuan Technology expects a year-on-year increase in net profit of 16%-26% for 2025, with significant growth in its electric vehicle business [1]